146 related articles for article (PubMed ID: 37805626)
1. Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry.
Koresawa-Shimizu R; Suzuki R; Uehara Y; Hiramoto N; Sawa M; Fukuda T; Kataoka K; Kanda Y; Oyake T; Kubota Y; Uchida N; Yano S; Kobayashi H; Tanaka J; Atsuta Y; Kondo E
Bone Marrow Transplant; 2024 Jan; 59(1):125-127. PubMed ID: 37805626
[No Abstract] [Full Text] [Related]
2. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation.
Sehn LH; Antin JH; Shulman LN; Mauch P; Elias A; Kadin ME; Wheeler C
Blood; 1998 Jan; 91(2):717-23. PubMed ID: 9427731
[TBL] [Abstract][Full Text] [Related]
3. Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?
Gisselbrecht C; Sibon D
Br J Haematol; 2023 Jan; 200(1):13-14. PubMed ID: 36120952
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.
Chihara D; Izutsu K; Kondo E; Sakai R; Mizuta S; Yokoyama K; Kaneko H; Kato K; Hasegawa Y; Chou T; Sugahara H; Henzan H; Sakamaki H; Suzuki R; Suzumiya J
Biol Blood Marrow Transplant; 2014 May; 20(5):684-9. PubMed ID: 24492141
[TBL] [Abstract][Full Text] [Related]
5. High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey.
Kim SW; Asakura Y; Tajima K; Iwai T; Taji H; Chou T; Morishima Y; Suzumiya J; Sakamaki H; Suzuki R; Fukuda T
Int J Hematol; 2020 Feb; 111(2):256-266. PubMed ID: 31732878
[TBL] [Abstract][Full Text] [Related]
6. LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre.
Pavlů J; Auner HW; Ellis S; Szydlo RM; Giles C; Contento A; Rahemtulla A; Apperley JF; Naresh K; MacDonald DH; Kanfer EJ
Hematol Oncol; 2011 Jun; 29(2):75-80. PubMed ID: 20635327
[TBL] [Abstract][Full Text] [Related]
7. Autologous hematopoietic stem cell transplantation as first-line consolidation therapy can improve the prognosis of diffuse large B-cell lymphoma with high expression of MYC protein.
Hu K; Gao JJ; Li QH; Tian L; Wan W; Zhao W; Wang JJ; Fu L
Kaohsiung J Med Sci; 2019 Jul; 35(7):425-431. PubMed ID: 31050117
[TBL] [Abstract][Full Text] [Related]
8. Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy.
Yang JC; Scordo M; Chau KW; Sauter CS; Yahalom J
Bone Marrow Transplant; 2022 Jun; 57(6):1038-1041. PubMed ID: 35430591
[No Abstract] [Full Text] [Related]
9. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
10. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Nieto Y; Valdez BC; Thall PF; Ahmed S; Jones RB; Hosing C; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Alousi A; Shah N; Bashir Q; Liu Y; Oki Y; Hagemeister F; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1914-20. PubMed ID: 26071868
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Briones J; Novelli S; García-Marco JA; Tomás JF; Bernal T; Grande C; Canales MA; Torres A; Moraleda JM; Panizo C; Jarque I; Palmero F; Hernández M; González-Barca E; López D; Caballero D;
Haematologica; 2014 Mar; 99(3):505-10. PubMed ID: 24162789
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study.
Yui S; Wakita S; Nagata Y; Kuribayashi Y; Asayama T; Fujiwara Y; Sakaguchi M; Yamanaka S; Marumo A; Omori I; Kinoshita R; Onai D; Sunakawa M; Kaito Y; Inai K; Tokura T; Takeyoshi A; Yasuda S; Honma S; Nakayama K; Hirakawa T; Arai K; Kitano T; Okamoto M; Inokuchi K; Yamaguchi H
Asia Pac J Clin Oncol; 2023 Feb; 19(1):136-148. PubMed ID: 35599446
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.
Kuruvilla J; Pintilie M; Tsang R; Nagy T; Keating A; Crump M
Leuk Lymphoma; 2008 Jul; 49(7):1329-36. PubMed ID: 18604722
[TBL] [Abstract][Full Text] [Related]
14. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
[TBL] [Abstract][Full Text] [Related]
15. Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma.
Matsuo T; Tanaka T; Fujii N
J Clin Exp Hematop; 2017; 56(3):170-175. PubMed ID: 28331132
[TBL] [Abstract][Full Text] [Related]
16. The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.
Rodrigues CA; Patah PA; Novis YA; Hosing C; de Lima M
Curr Hematol Malig Rep; 2011 Mar; 6(1):47-57. PubMed ID: 21190142
[TBL] [Abstract][Full Text] [Related]
17. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma.
Villanueva ML; Vose JM
Clin Adv Hematol Oncol; 2006 Jul; 4(7):521-30. PubMed ID: 17147239
[TBL] [Abstract][Full Text] [Related]
18. [Progress of Auto-HSCT for Treatment of DLBCL--Review].
Wang X; Xia B; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1841-1846. PubMed ID: 30501731
[TBL] [Abstract][Full Text] [Related]
19. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R;
Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
